Frederick M. Hudson - 24 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
25 Feb 2026, 16:56:53 UTC
Prior SEC filing
20 Feb 2026
Next SEC filing
16 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

Frederick M. Hudson filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 25 Feb 2026.

Key facts

  • This page summarizes Frederick M. Hudson's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 25 Feb 2026, 16:56.

Change

  • Previous filing in this sequence was filed on 20 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001438462 Primary reporting owner

Hudson Frederick M.

Relationship
Director
Address
C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Signature date
25 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN transaction

Common Stock

Award

Transaction value
$0
Shares
+4,475
Change %
+7.3%
Price
$0.000000
Shares after
65,782
Date
24 Feb 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Restricted Stock Unit

Disposed to Issuer

Transaction value
$0
Shares
-4,475
Change %
-100%
Price
$0.000000
Shares after
0
Date
24 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,475
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F2

These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .